Physician profile
Huma Baqui
NPI 1225328701
$11,126.38
in general payments reported to CMS, 2019-2025
74 companies · $40.51 in 2025
The $40.51 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,188 · 2020: $1,515 · 2021: $2,184 · 2022: $2,276 · 2023: $2,225 · 2024: $1,698 · 2025: $40.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,963.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,071.21 | 2019-2024 | Qulipta, Botox, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $903.86 | 2019-2024 | Austedo Xr, Austedo |
| Biogen, INC. | $875.39 | 2019-2024 | Vumerity, Tysabri, Skyclarys |
| Ucb, INC. | $786.53 | 2019-2024 | Briviact, Rystiggo, Nayzilam |
| Pfizer INC. | $607.28 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $577.37 | 2020-2024 | |
| Lilly USA, LLC | $513.20 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Alexion Pharmaceuticals, INC. | $398.87 | 2019-2024 | Ultomiris, Soliris |
| Janssen Pharmaceuticals, INC | $363.93 | 2020-2023 | Ponvory |
| Biohaven Pharmaceutical Holding Company Ltd. | $325.04 | 2022 | |
| Celgene Corporation | $316.47 | 2021-2024 | Zeposia |
| Supernus Pharmaceuticals, INC. | $225.90 | 2019-2021 | |
| Lundbeck LLC | $218.69 | 2020-2024 | Vyepti, Rexulti |
| Biohaven Pharmaceuticals, INC. | $216.92 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $215.46 | 2019-2024 | Rytary |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huma Baqui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.